PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Finerenone Benefits Extend Across CKD Etiologies in 14,574-Patient Pooled Analysis

finerenonemineralocorticoid receptor antagonistchronic kidney diseasehyperkalaemiaindividual participant data meta-analysisFIDELIO-DKDFIGARO-DKDFIND-CKDnephrologycardiovascular outcomes Nephrology / Renal Pharmacy

Background Information

Finerenone cuts kidney decline risk by nearly a quarter.

Chronic kidney disease (CKD) is a major public health issue, and effective treatments are needed to prevent progression. Finerenone reduced the risk of kidney and cardiovascular outcomes by 24% and 20%, respectively, compared to placebo. The study supports the use of finerenone regardless of CKD aetiology and baseline conditions, though hyperkalaemia is a consideration. Finerenone effectively reduces CKD progression and cardiovascular risks across diverse patient populations.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Neuen BL, Heerspink HJL, Perkovic V, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Jongs N, Smeijer JD, Brinker M, Ahlers C, Lage A, Horvat-Bröcker A, Schloemer P, Eissing T, Dayoub R, Lawatscheck R, Agarwal R, FIND-CKD, FIDELIO-DKD and FIGARO-DKD Investigators

Citation: Neuen BL, Heerspink HJL, Perkovic V, et al. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY). Lancet (London, England). 2026;407(10546):2375-2386. doi:10.1016/S0140-6736(26)01009-3

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.